GlassScriptPhysician profile
Rufina P Miel
NPI 1063470391
$102,541.90
in general payments reported to CMS, 2019-2025
100 companies · $29K in 2025
The $29K reported for 2025 was more than what 94% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,946 · 2020: $14K · 2021: $6,901 · 2022: $7,038 · 2023: $13K · 2024: $28K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $31K · Food and Beverage: $27K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,912 · Travel and Lodging: $3,382 · Long Term Medical Supply Or Device Loan: $1,613 · Honoraria: $1,600 · Education: $663 · Gift: $55.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $30,657.50 |
| Food and Beverage | $26,701.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,912.00 |
| Travel and Lodging | $3,381.93 |
| Long Term Medical Supply Or Device Loan | $1,613.05 |
| Honoraria | $1,600.00 |
| Education | $662.72 |
| Gift | $55.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $18,793.77 | 2019-2025 | Imfinzi, Tagrisso, Truqap |
| Janssen Biotech, INC. | $8,170.73 | 2019-2025 | Tecvayli, Rybrevant, Darzalex |
| Celgene Corporation | $6,636.62 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Gilead Sciences, INC. | $5,422.59 | 2021-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $5,185.64 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Genzyme Corporation | $4,869.00 | 2019-2025 | |
| Avyxa Pharma, LLC | $4,549.24 | 2025 | |
| Novartis Pharmaceuticals Corporation | $4,019.07 | 2019-2025 | |
| Incyte Corporation | $3,909.55 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Pfizer INC. | $3,323.47 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $3,101.98 | 2020-2025 | Xpovio |
| Puma Biotechnology, INC. | $2,546.61 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $2,062.37 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $1,746.28 | 2019-2025 | Alunbrig, Fruzaqla, Iclusig |
| Eisai INC. | $1,660.70 | 2019-2025 |
Show all 100 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $1,658.69 | 2023 | Firdapse |
| E.R. Squibb & Sons, L.L.C. | $1,644.79 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Genmab U.S., INC. | $1,575.00 | 2025 | Epkinly |
| Daiichi Sankyo INC. | $1,349.99 | 2020-2025 | Enhertu, Datroway, Vanflyta |
| Seagen INC. | $1,100.18 | 2019-2025 | Padcev, Adcetris, Tukysa |
| Lilly USA, LLC | $1,001.92 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Pharmacyclics LLC, An Abbvie Company | $948.92 | 2019-2023 | Imbruvica, Epkinly |
| Amgen INC. | $902.49 | 2019-2023 | Nplate, Vectibix, Lumakras |
| Genentech USA, INC. | $801.31 | 2019-2025 | Phesgo, Polivy, Tecentriq |
| Astellas Pharma US INC | $800.92 | 2019-2025 | Xospata, Xtandi, Vyloy |
| Pharmaessentia USA Corporation | $740.95 | 2022-2025 | Besremi |
| Sobi, INC | $698.89 | 2022-2025 | |
| Abbvie INC. | $669.97 | 2019-2025 | |
| Array Biopharma INC | $663.50 | 2019-2025 | Braftovi, Mektovi, Tukysa |
| Exelixis INC. | $624.87 | 2019-2025 | Cabometyx |
| Emd Serono, INC. | $508.04 | 2019-2025 | Bavencio |
| Secura Bio, INC. | $465.14 | 2020-2024 | Copiktra |
| Novocure INC. | $458.94 | 2020-2025 | Optune Gio, Optune, Optune Lua (Novottf-200t) |
| Bayer Healthcare Pharmaceuticals INC. | $448.33 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $403.98 | 2023-2025 | Orgovyx |
| Tesaro, INC. | $397.14 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $375.60 | 2019-2025 | Gilotrif |
| Janssen Scientific Affairs, LLC | $372.34 | 2025 | Rybrevant |
| Regeneron Healthcare Solutions, INC. | $360.67 | 2020-2025 | Libtayo |
| Aveo Pharmaceuticals, INC. | $354.30 | 2021-2025 | Fotivda |
| Ipsen Biopharmaceuticals, INC | $347.63 | 2019-2025 | Tazverik, Onivyde, Somatuline Depot |
| Beigene USA, INC. | $342.22 | 2021-2024 | Brukinsa |
| Kite Pharma, INC. | $330.71 | 2020-2023 | Yescarta |
| Alexion Pharmaceuticals, INC. | $244.96 | 2019-2025 | Ultomiris |
| Verastem, INC. | $239.41 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $235.64 | 2022-2025 | |
| Stemline Therapeutics INC. | $231.45 | 2020-2025 | Orserdu |
| Taiho Oncology, INC. | $231.35 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $230.52 | 2020-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Foundation Medicine, INC. | $206.07 | 2019-2023 | |
| Cti Biopharma Corp. | $203.19 | 2022-2023 | Vonjo |
| Adc Therapeutics America, INC. | $192.42 | 2022-2025 | |
| Csl Behring | $189.53 | 2019-2022 | |
| Athenex Pharmaceutical Division, LLC | $175.00 | 2020 | |
| Servier Pharmaceuticals LLC | $167.41 | 2021-2025 | |
| Agios Pharmaceuticals, INC. | $165.77 | 2020-2025 | Pyrukynd |
| Myovant Sciences INC. | $156.39 | 2021-2022 | |
| Blueprint Medicines Corporation | $155.39 | 2020-2023 | Ayvakit |
| Dova Pharmaceuticals | $152.62 | 2020-2021 | |
| Deciphera Pharmaceuticals INC. | $152.33 | 2022-2025 | Qinlock, Romvimza |
| Syndax Pharmaceuticals, INC. | $150.70 | 2025 | Revuforj |
| Caris Mpi, INC. | $148.56 | 2025 | Mi Cancer Seek |
| Ge Healthcare | $138.37 | 2021-2025 | |
| Geron Corporation | $120.99 | 2025 | Rytelo |
| Recordati_rare_diseases_inc. | $120.68 | 2023-2025 | Sylvant, Enjaymo |
| Dendreon Pharmaceuticals LLC | $116.91 | 2019-2025 | Provenge |
| G1 Therapeutics, INC. | $111.53 | 2022-2023 | Cosela |
| Fennec Pharmaceuticals, INC. | $107.11 | 2024-2025 | Fyarro, Pedmark |
| Menarini Silicon Biosystems, INC. | $102.44 | 2024 | |
| Pharmacosmos Therapeutics INC. | $83.59 | 2024-2025 | Monoferric, Cosela |
| Epizyme, INC. | $80.67 | 2021-2022 | |
| Morphosys, US INC. | $80.24 | 2022 | |
| Myriad Genetic Laboratories, INC. | $74.53 | 2022-2024 | Myrisk |
| Apellis Pharmaceuticals, INC. | $73.33 | 2023-2024 | Empaveli |
| Acrotech Biopharma INC. | $70.64 | 2021-2023 | Beleodaq |
| Mirati Therapeutics, INC. | $69.31 | 2023-2024 | Krazati |
| Eusa Pharma (US) LLC | $65.03 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $64.12 | 2020-2022 | |
| Coherus Oncology, INC. | $61.40 | 2024-2025 | Loqtorzi |
| Beone Medicines USA, INC. | $61.35 | 2025 | Brukinsa |
| Clovis Oncology, INC. | $56.72 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $56.62 | 2019 | |
| Emmaus Medical, INC. | $52.43 | 2021-2023 | Endari |
| Amag Pharmaceuticals, INC. | $50.98 | 2020-2021 | |
| Immunogen, INC. | $47.98 | 2023 | Elahere |
| Tersera Therapeutics LLC | $44.92 | 2021-2022 | |
| Adaptive Biotechnologies Corporation | $41.85 | 2021-2025 | Clonoseq |
| Telix Pharmaceuticals | $41.32 | 2022-2023 | Illuccix |
| Iovance Biotherapeutics, INC. | $41.06 | 2025 | Amtagvi |
| Aurobindo Pharma USA, INC. | $40.91 | 2019-2020 | |
| Boston Scientific Corporation | $40.62 | 2025 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial), Therasphere Y90 Glass Microspheres 10 Gbq |
| Sun Pharmaceutical Industries INC. | $36.47 | 2019-2022 | |
| Sirtex Medical INC | $36.13 | 2020-2022 | |
| Tempus Ai, INC | $27.80 | 2024 | |
| Legend Biotech USA INC. | $26.79 | 2024 | |
| Invivyd INC | $26.61 | 2025 | Pemgarda |
| West Therapeutics Development, LLC | $24.63 | 2019 | |
| Mallinckrodt Hospital Products INC. | $23.89 | 2020 | |
| Kyowa Kirin, INC. | $23.55 | 2023 | Poteligeo |
| Azurity Pharmaceuticals, INC. | $22.58 | 2025 | Danziten |
Drugs and devices associated with these payments
Imfinzi $5,503Trodelvy $4,921Tecvayli $3,637Rybrevant $3,634Jemperli $2,855Kisqali $2,133Tagrisso $2,129Truqap $2,010Epkinly $1,820Firdapse $1,659Darzalex $1,567Ibrance $1,490Zejula $1,387Lynparza $1,154Keytruda $1,063Imbruvica $736Lenvima $690Enhertu $680Opdivo $664Braftovi $658Orgovyx $597Ojjaara $551Mektovi $533Vonjo $509Carvykti $503Besremi $494Jakafi $493Alunbrig $467Copiktra $428Sarclisa $418Tukysa $392Monjuvi $378Reblozyl $363Xtandi $362Padcev $355Cabometyx $338Erleada $315Optune Gio $308Fruzaqla $295Talvey $292Verzenio $284Pluvicto $284Xpovio $279Jaypirca $260Libtayo $233Fabhalta $228Welireg $227Iclusig $223Orserdu $220Brukinsa $202Elrexfio $198Elahere $187Akeega $180Pemazyre $178Opdualag $170Lorbrena $167Tivdak $166Piqray $160Lonsurf $156Inqovi $156Fotivda $155Wayrilz $154Phesgo $154Promacta $153Talzenna $152Mi Cancer Seek $149Adcetris $148Scemblix $147Doptelet $144Bavencio $143Revuforj $143Pomalyst $136Pyrukynd $136Zepzelca $128Tazverik $125Retevmo $123Ultomiris $123Rytelo $121Somatuline Depot $121Onivyde $121Datroway $120Zynlonta $115Bosulif $105Cosela $104Cellsearch $102Stivarga $102Polivy $101Blenrep $98.50Tecentriq $96.11Provenge $93.46Calquence $90.47Tavalisse $89.33Xospata $87.00Fyarro $83.68Lutathera $83.23Vitrakvi $81.27Sylvant $81.14Besponsa $78.16Qinlock $76.14Rezlidhia $74.23
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rufina Miel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.